NCT06561685 2026-02-10A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Recruiting340 enrolled
NCT07218003 2025-10-24A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo TherapeuticsPhase 1 Recruiting149 enrolled
NCT05585320 2025-09-02A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsImmuneering CorporationPhase 1/2 Active not recruiting209 enrolled
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled
NCT05128487 2024-11-25A Study of NDI 1150-101 in Patients With Solid TumorsNimbus TherapeuticsPhase 1/2 Active not recruiting106 enrolled
NCT03861793 2024-03-05A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)Mural Oncology, IncPhase 1/2 Completed116 enrolled